Coelho Rogerio Vivaldi - 28 Feb 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
PRESIDENT AND CEO, Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
01 Mar 2023, 15:43:45 UTC
Previous filing
21 Jun 2022
Next filing
09 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +460,000 $0.000000 460,000 28 Feb 2023 Common Stock 460,000 $1.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested.